Startup profile · funding coverage
Rightway funding, valuation and investors
Pharmacy-benefit management and care navigation for employers.
Keep track of Rightway
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series E
$155M · September 24, 2026
Latest known valuation
Undisclosed
Series E · September 24, 2026
Total disclosed equity funding
$155M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
growth · New York, United States
Overview
Rightway combines pharmacy-benefit management with care navigation. Its model emphasizes transparent pricing, rebate pass-through and clinical support for members.
Why Rightway is interesting
Rightway is challenging traditional pharmacy-benefit managers with a model designed to align employer costs, drug selection and member support.
Product & use cases
- Pharmacy-benefit management for employers.
- Healthcare navigation and clinical member support.
Key facts
- Raised $155 million Series E in September 2026.
- Company reports 45 Fortune 500 customers.
Funding history (newest first)
Series E
2026-09-24 $155M Valuation: UndisclosedInvestors in our directory
Funds linked from Rightway's profile — open a fund page for stage focus and related deal articles.
Competitive landscape
-
CVS Caremark incumbent
Large incumbent pharmacy-benefit manager.
-
Express Scripts incumbent
Large incumbent pharmacy-benefit manager.
-
Transcarent adjacent
Employer healthcare-navigation platform.
Industries
Market / IPO context
Editorial / static context — not a live quote.
Related funding articles
Venture Capital Tracker pieces that cover Rightway's financing or category context.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.